KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Amortizatization of Intangibles: 2010-2020

Historic Amortizatization of Intangibles for TherapeuticsMD (TXMD) over the last 8 years, with Mar 2020 value amounting to $63,155.

  • TherapeuticsMD's Amortizatization of Intangibles rose 56.15% to $63,155 in Q1 2020 from the same period last year, while for Mar 2020 it was $220,304, marking a year-over-year increase of 67.25%. This contributed to the annual value of $197,593 for FY2019, which is 75.68% up from last year.
  • As of Q1 2020, TherapeuticsMD's Amortizatization of Intangibles stood at $63,155, which was up 10.05% from $57,387 recorded in Q4 2019.
  • TherapeuticsMD's Amortizatization of Intangibles' 5-year high stood at $63,155 during Q1 2020, with a 5-year trough of $11,234 in Q1 2016.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $40,444 (2019), whereas its average is $41,469.
  • Data for TherapeuticsMD's Amortizatization of Intangibles shows a peak YoY surged of 95.37% (in 2019) over the last 5 years.
  • Quarterly analysis of 5 years shows TherapeuticsMD's Amortizatization of Intangibles stood at $15,985 in 2016, then rose by 20.08% to $19,195 in 2017, then spiked by 84.17% to $35,351 in 2018, then surged by 62.33% to $57,387 in 2019, then skyrocketed by 56.15% to $63,155 in 2020.
  • Its Amortizatization of Intangibles stands at $63,155 for Q1 2020, versus $57,387 for Q4 2019 and $51,259 for Q3 2019.